1. Medicines
  2. Ophthalmology
  3. LUCENTIS® (ranibizumab)
  4. Resources
  5. Resources for HCPs
  6. The role of LUCENTIS in restarting DMO and wAMD clinics

Prescribing information

 

The role of LUCENTIS in restarting DMO and wAMD clinics

In this video, Mr Mandeep Bindra explains the steps that the Medical Retina team undertook during the COVID-19 pandemic to ensure continuation of patient care. He also discusses plans to restart DMO clinics and shares advice on how to maintain social distancing and increase the efficiency of patient flow through the clinic.

Indications1

LUCENTIS 0.5 mg is indicated in adults for:

  • The treatment of neovascular (wet) age-related macular degeneration (AMD)
  • The treatment of visual impairment due to diabetic macular oedema (DMO)
  • The treatment of proliferative diabetic retinopathy (PDR)
  • The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)
  • The treatment of visual impairment due to choroidal neovascularisation (CNV).

LUCENTIS 0.2 mg is indicated in preterm infants for:

  • The treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.

 

DMO, diabetic macular oedema; HCP, healthcare professional; wAMD, wet age-related macular degeneration.

Reference

  1. LUCENTIS® (ranibizumab) Summary of Product Characteristics, July 2020.
LUC20-C030w(1) November 2020.
Ophthalmology
Video
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]